Reported about 19 hours ago
Danish pharmaceutical company Novo Nordisk is expanding its partnership with U.S. tech firm Valo Health to develop new obesity treatments using artificial intelligence, following underwhelming trial results for its drug CagriSema. The collaboration, which aims to increase the number of new treatments from 11 to 20 for obesity, type 2 diabetes, and cardiovascular diseases, could tap into a $150 billion market in the next decade, with Valo set to receive substantial payments under the new agreement.
Source: YAHOO